Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20707235 | 1.00 | CA2 (0.41) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL21409613 | 0.98 | CA2 (0.40) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL21409717 | 0.98 | CA2 (0.40) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL2757771 | 0.98 | CA2 (0.40) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL9152721 | 0.95 | CA2 (0.38) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL929572 | 0.94 | CA2 (0.42) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL1243925 | 0.94 | CA2 (0.42) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL4929770 | 0.94 | CA2 (0.42) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL9152542 | 0.90 | CA2 (0.49) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 | |
| SCHEMBL649656 | 0.86 | CA2 (0.44) | CA2ALDH1A1TMEM97SIGMAR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682178-A1 | MATERIAL UNDER THE FORM OF A NETWORK OF CROSSLINKED POLYMER(S) EXHIBITING GOOD MECHANICAL PROPERTIES BASED ON DIOXAZABOROCANES | PARIS SCIENCES ET LETTRES (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-3839028-B1 | CLEANING PRODUCT | PROCTER & GAMBLE (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20250011622-A1 | BLOCK COPOLYMER, UNDERCOAT AGENT, RESIN COMPOSITION FOR FORMING PHASE-SEPARATED STRUCTURE, AND METHOD FOR PRODUCING STRUCTURE BODY INCLUDING PHASE-SEPARATED STRUCTURE | TOKYO OHKA KOGYO CO LTD (JP) | 2025-01-09 | — | — | US | disclosed |
| US-20250011616-A1 | METHOD FOR PRODUCING STRUCTURE BODY INCLUDING PHASE-SEPARATED STRUCTURE, AND COMPOSITION | TOKYO OHKA KOGYO CO LTD (JP) | 2025-01-09 | — | — | US | disclosed |
| WO-2024031051-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11859150-B2 | Thermoassociative and exchangeable copolymers, composition comprising same | TOTAL MARKETING SERVICES (FR) | 2024-01-02 | — | — | US | disclosed |
| US-11859150-B2 | Thermoassociative and exchangeable copolymers, composition comprising same | TOTAL MARKETING SERVICES (FR) | 2024-01-02 | — | — | US | disclosed |
| US-11834627-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023182309-A1 | COMPOUND, POLYMER, COMPOSITION, RUST-PREVENTIVE AGENT, ADHESIVE AGENT, AND COATING AGENT | 三井化学株式会社 | 2023-09-28 | — | — | WO | disclosed |
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (FR) | 2023-06-20 | — | — | US | disclosed |
| EP-0075850-A2 | Pharmaceutical preparations containing vicinal dihydroxyalkyl xanthines, process for the preparation of the xanthines and the appropriate intermediates therefor | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-04-06 | — | — | EP | disclosed |
| EP-0072872-A1 | 1-Hydroxymethyl-prosten-1-ol derivatives | AMERICAN CYANAMID COMPANY (US) | 1983-03-02 | — | — | EP | disclosed |
| US-4310700-A | 1-Hydroxylmethyl-11-deoxy-16-hydroxy-prosten-1-ol-derivatives | AMERICAN CYANAMID COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4291174-A | PROSTAGLANDINS | AMERICAN CYANAMID COMPANY (US) | 1981-09-22 | — | — | US | disclosed |
| US-4291175-A | PROSTAGLANDINS USEFUL AS HYPOTENSIVE AGENTS, GASTRIC SECRETORY AND PLATELET AGGREGATION INHIBITORS, AND BRONCHODILATORS | AMERICAN CYANAMID COMPANY (US) | 1981-09-22 | — | — | US | disclosed |
| US-4289910-A | PROSTAGLANDIN ANALOGS | AMERICAN CYANAMID COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4288630-A | HYPOTENSIVES, ANTISECRETORY, ANTICOAGULANTS, BRONCHODILATORS | AMERICAN CYANAMID COMPANY (US) | 1981-09-08 | — | — | US | disclosed |
| US-4288632-A | HYPOTENSIVES, ANTISECRETORY, ANTICOAGULANTS, BRONCHODILATORS | AMERICAN CYANAMID COMPANY (US) | 1981-09-08 | — | — | US | disclosed |
| US-4288633-A | PROSTAGLANDIN ANALOGS; ANTISECRETORY, HYPOTENSIVE, ANTICOAGULANT, BRONCHODILATING | AMERICAN CYANAMID COMPANY (US) | 1981-09-08 | — | — | US | disclosed |
| US-4288629-A | PROSTAGLANDIN ANALOGS; HYPOTENSIVE, ANTISECRETORY, ANTICOAGULANT, BRONCHODILATING | AMERICAN CYANAMID COMPANY (US) | 1981-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680074-B2 | Compounds, functionalised dioxaborolane or dioxaborinane derivatives, method for preparing same and uses thereof | RDX, XDH, NOX4 | CA2 1498/4885ALDH1A1 944/4885TMEM97 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.